Binghe Xu1, Zhimin Shao2, Shui Wang3, Zefei Jiang4, Xichun Hu2, Xiaohua Zhang5, Xiru Li6, Jinping Liu7, Mengquan Li8, Shu Wang9. 1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. 2. Fudan University Shanghai Cancer Hospital, Shanghai 200032, China. 3. Jiangsu Province Hospital, Nanjing 210029, China. 4. Affiliated Hospital of Chinese Academy of Military Medical Sciences, Beijing 100071, China. 5. the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. 6. Division of Breast Surgery, Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, China. 7. Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, China. 8. the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 9. Peking University People's Hospital, Beijing 100044, China.
Abstract
OBJECTIVE: Adjuvant docetaxel-based chemotherapy is frequently used for operable early breast cancer (EBC). This study investigated patterns of use of docetaxel (T) in real-life clinical practice in China. METHODS: This was a retrospective pooled analysis of the Asia-Pacific Breast Initiatives (APBI) I (2006-2008) and II (2009-2011) registries, and two Chinese observational studies; BC STATE (2011-2014) and BC Local Registry (2007-2010). Female Chinese adults (≥18 years) with operable breast cancer treated with docetaxel-based adjuvant chemotherapy were included in the analysis. Patients with metastatic disease were excluded. The primary endpoint was assessment of treatment patterns and patient profiles. A logistic regression analysis was conducted to identify factors associated with choice of adjuvant chemotherapy regimen. RESULTS: Data from 3,020 patients were included. The most frequently used adjuvant regimen was docetaxel/anthracycline combination [n=1,421 (47.1%); of whom 52.0% received T/epirubicin (E)/cyclophosphamide (C)], followed by docetaxel/other [n=705 (23.3%); of whom 72.8% received TC], docetaxel/anthracycline sequential [n=447 (14.8%); of whom 40.9% and 39.6% received 5-Fu/EC-T and EC-T, respectively], and " other" [n=447 (14.8%); of whom 91.5% received T]. A significant association was found between adjuvant therapy with docetaxel/anthracycline combination and patient weight, menopausal status and estrogen receptor status. CONCLUSIONS: Real-world data revealed that docetaxel/anthracycline combination is the most commonly used category of docetaxel-based adjuvant therapy for patients with operable breast cancer in China; of which TEC is the most frequently used regimen.
OBJECTIVE: Adjuvant docetaxel-based chemotherapy is frequently used for operable early breast cancer (EBC). This study investigated patterns of use of docetaxel (T) in real-life clinical practice in China. METHODS: This was a retrospective pooled analysis of the Asia-Pacific Breast Initiatives (APBI) I (2006-2008) and II (2009-2011) registries, and two Chinese observational studies; BC STATE (2011-2014) and BC Local Registry (2007-2010). Female Chinese adults (≥18 years) with operable breast cancer treated with docetaxel-based adjuvant chemotherapy were included in the analysis. Patients with metastatic disease were excluded. The primary endpoint was assessment of treatment patterns and patient profiles. A logistic regression analysis was conducted to identify factors associated with choice of adjuvant chemotherapy regimen. RESULTS: Data from 3,020 patients were included. The most frequently used adjuvant regimen was docetaxel/anthracycline combination [n=1,421 (47.1%); of whom 52.0% received T/epirubicin (E)/cyclophosphamide (C)], followed by docetaxel/other [n=705 (23.3%); of whom 72.8% received TC], docetaxel/anthracycline sequential [n=447 (14.8%); of whom 40.9% and 39.6% received 5-Fu/EC-T and EC-T, respectively], and " other" [n=447 (14.8%); of whom 91.5% received T]. A significant association was found between adjuvant therapy with docetaxel/anthracycline combination and patient weight, menopausal status and estrogen receptor status. CONCLUSIONS: Real-world data revealed that docetaxel/anthracycline combination is the most commonly used category of docetaxel-based adjuvant therapy for patients with operable breast cancer in China; of which TEC is the most frequently used regimen.
Entities:
Keywords:
Adjuvant chemotherapy; docetaxel; early-stage breast cancer
Authors: Sung-Bae Kim; Ahmed Sayeed; Antonio H Villalon; Zhe-Zhou Shen; Mazhar A Shah; Meng-Feng Hou; Duc Nguyen Ba Journal: Asia Pac J Clin Oncol Date: 2016-02-18 Impact factor: 2.601
Authors: Joanne L Blum; Patrick J Flynn; Greg Yothers; Lina Asmar; Charles E Geyer; Samuel A Jacobs; Nicholas J Robert; Judith O Hopkins; Joyce A O'Shaughnessy; Chau T Dang; Henry Leonidas Gómez; Louis Fehrenbacher; Svetislava J Vukelja; Alan P Lyss; Devchand Paul; Adam M Brufsky; Jong-Hyeon Jeong; Linda H Colangelo; Sandra M Swain; Eleftherios P Mamounas; Stephen E Jones; Norman Wolmark Journal: J Clin Oncol Date: 2017-04-11 Impact factor: 44.544
Authors: Neelima Denduluri; Mark R Somerfield; Andrea Eisen; Jamie N Holloway; Arti Hurria; Tari A King; Gary H Lyman; Ann H Partridge; Melinda L Telli; Maureen E Trudeau; Antonio C Wolff Journal: J Clin Oncol Date: 2016-04-18 Impact factor: 44.544
Authors: J R Mackey; T Pieńkowski; J Crown; S Sadeghi; M Martin; A Chan; M Saleh; S Sehdev; L Provencher; V Semiglazov; M F Press; G Sauter; M Lindsay; V Houé; M Buyse; P Drevot; S Hitier; S Bensfia; W Eiermann Journal: Ann Oncol Date: 2016-03-02 Impact factor: 32.976
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321